secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
CIK:        0000315545
Form:       8-K
Filed at:   2022-04-19T23:59:59+00:00
Accession:  0001493152-22-010445
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Provectus seeks approval for 1-for-10 to 1-for-50 reverse stock split at June 22 annual meeting
--------------------------------------------------------------------------------

- Filed preliminary proxy; meeting scheduled for June 22, 2022; record date April 25, 2022.
- Reverse split ratio range is 1-for-10 to 1-for-50, applies to common stock and Series D/D-1 preferred.
- Authorized share reduction proposal contingent on reverse split approval; both require stockholder approval.
- Stockholders also vote on director election, executive compensation, and auditor ratification.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/315545/000149315222010445/0001493152-22-010445-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/315545/000149315222010445/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-010445

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer